Clinical trials: aGVHD
aGVHD, cGVHD
Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
The purpose of this study is to determine the efficacy and safety of combined ATG #antithymocyte globulin # regimen (5mg/kg divided from day -5 to day -2) for aGVHD(acute graft-versus-host disease ) prophylaxis in matched sibling…
- Trial name
- NCT05214066
- Testing
- Rabbit ATG
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
aGVHD, Stem Cell Transplant Complications
Low Dose Ruxolitinib in Combination With Methylprednisolone
This study is to determine the efficacy and safety of combined Low dose Ruxolitinib With Methylprednisone as Initial Therapy for the aGVHD(acute graft-versus-host disease )
- Trial name
- NCT04397367
- Testing
- Ruxolitinib 10 mg twice a day combined with Corticosteroids, Ruxolitinib 5 mg twice a day combined with Corticosteroids, Ruxolitinib 5 mg once a day combined with Corticosteroids
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Chinese PLA General Hospital
Prevention aGVHD
An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)
A prospective, open-label, phase 2a study, to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of multiple doses of Cannabidiol (CBD) in participants Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic…
- Trial name
- NCT03840512
- Testing
- CBD
- Where
- 5 sites in Australia, Israel
- Volunteers
- 36 people
- Sponsor
- Kalytera Therapeutics Israel, Ltd.
Steroid-resistant Severe aGVHD
MSC for Severe aGVHD
Steroid-resistant acute graft-versus-host disease (aGVHD) is one of the most severe complications in the setting of allogeneic hematopoietic stem cell transplantation (HSCT), which cannot be significant benefit from the…
- Trial name
- NCT03631589
- Testing
- MSCs
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University
aGVHD
Biomarker Study for Prediction of aGVHD
This is a prospective study in patients receiving allogeneic stem cell transplantation. The blood samples on Day-14, -7, 0 and every 7 days until D100 were collected together with clinical data.
- Trial name
- NCT03614143
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Peripheral Blood Stem Cell Transplantation, aGVHD
Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD
aGVHD remains as complication in patients after allogeneic stem cell transplantation. Methylprednisolone at 1~2mg/kg is considered as standard first-line treatment.
- Trial name
- NCT02848105
- Testing
- VPA
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD
This study is to assess the efficacy of Neihulizumab versus "conventional therapy" and to evaluate safety, pharmacokinetics and immunogenicity in treating steroid-refractory acute Graft-vs-Host Disease
- Trial name
- NCT02694770
- Testing
- Neihulizumab Treatment, Conventional Treatment
- Where
- 2 sites in United States
- Sponsor
- AbGenomics B.V Taiwan Branch